There are currently 53 active clinical trials seeking participants for Atopic Dermatitis research studies. The states with the highest number of trials for Atopic Dermatitis participants are California, Florida, Texas and Ontario.
A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis
NCT06436183
Recruiting
This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety of camoteskimab in adults with moderate to severe AD.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/02/2025
Locations: Medical Dermatology Specialists, PC/US Dermatology Partners, Phoenix, Arizona +34 locations
Conditions: Atopic Dermatitis, Atopic, Dermatitis, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic
Register for Updates
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
NCT06627335
Recruiting
This study is to assess infant outcomes of women with AD who were exposed to ruxolitinib cream during pregnancy compared with a control cohort of women with AD who were exposed to a topical corticosteroid (TCS) during pregnancy.
Gender:
FEMALE
Ages:
14 years and above
Trial Updated:
12/05/2024
Locations: Syneos Health (remote site), Morrisville, North Carolina
Conditions: Pregnancy Related, Atopic Dermatitis
Register for Updates
Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population
NCT06259669
Recruiting
This observational (enrollment into the registry while the pregnancy is ongoing) study is being conducted to compare the frequency of major congenital malformation (MCM)s among infants of women exposed to ruxolitinib cream during pregnancy with infants of women not exposed to ruxolitinib cream during pregnancy.
Gender:
FEMALE
Ages:
Between 15 years and 50 years
Trial Updated:
12/05/2024
Locations: Syneos Health (remote site), Morrisville, North Carolina
Conditions: Pregnancy Related, Atopic Dermatitis
Register for Updates
Ethnic Differences in Mechanisms of Action of Dupilumab
NCT05268107
Recruiting
Previous research has shown that Asian and African Americans are more likely to develop atopic dermatitis (AD) than their Caucasian counterparts. However, limited information is known about AD in Asian and African American populations because most molecular studies have focused on Caucasians with AD. This trial will determine differences in inflammatory responses to dupilumab between Caucasian, Asian, and African American patients with AD. The central hypothesis of this study is that ethnic di... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Atopic Dermatitis
Register for Updates
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
NCT05995964
Recruiting
The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash, caused by a skin reaction. This study is seeking participants who: * are 18 years of age or more. * Were confirmed to have AD at least 6 months ago. * Are not having an effective treatment result from medicines that are applied on skin for AD. * Are considered by their doctors to have moderate to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2024
Locations: Allervie Clinical Research, Birmingham, Alabama +72 locations
Conditions: Atopic Dermatitis
Register for Updates
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
NCT03936335
Recruiting
The objective of this study is to describe and compare the incidence of adverse pregnancy outcomes (spontaneous abortion/miscarriage, stillbirth) and prevalence of infant outcomes (major congenital malformations \[MCMs\], small for gestational age \[SGA\]) in women with AD who are treated with dupilumab during pregnancy relative to women with AD who are not treated with dupilumab during pregnancy.
Gender:
FEMALE
Ages:
Between 18 years and 49 years
Trial Updated:
10/16/2024
Locations: Regeneron Research Site, Boston, Massachusetts
Conditions: Adverse Pregnancy Outcomes, Atopic Dermatitis
Register for Updates
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
NCT05042258
Recruiting
Single center, prospective, Open label study of sleep, pruritus and circadian function pre/post 12-weeks of dupilumab treatment in children 6-17 years old
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
10/03/2024
Locations: Lurie Children's Hospital/Northwestern University, Chicago, Illinois
Conditions: Atopic Dermatitis, Sleep Disturbance
Register for Updates
Michigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project
NCT06300697
Recruiting
This study will explore potential links between atopic dermatitis and food allergy. This information will be useful to determine atopic dermatitis and food allergy share unique biochemical or genetic identifiers useful for diagnosing and treatments in the future. This is a mechanistic study consisting of obtaining blood and skin samples from participants at baseline. Individuals may also undergo a clinically indicated oral food challenge and have blood and skin samples collected at various time... Read More
Gender:
ALL
Ages:
Between 10 years and 55 years
Trial Updated:
09/17/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Atopic Dermatitis, Food Allergy, Healthy
Register for Updates
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
NCT06055361
Recruiting
The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of a single and multiple SC dose of BxC-I17e in patients with moderate to severe atopic dermatitis (AD)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2024
Locations: Arkansas Research Trials, North Little Rock, Arkansas +2 locations
Conditions: Atopic Dermatitis
Register for Updates
Molecular Signatures of Cutaneous Dupilumab Response
NCT05858619
Recruiting
This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2024
Locations: University of California, San Francisco, San Francisco, California
Conditions: Atopic Dermatitis
Register for Updates
Study of Skin Microbiome in AD and PS Patients
NCT04170244
Recruiting
Everybody's skin has bacteria that normally lives on it. Previous research has shown that people with eczema (or atopic dermatitis \[AD\]) have much higher concentrations of a certain bacteria (S. aureus), especially when their disease is active but little is known about the role that this bacteria plays in psoriasis (i.e. disease severity, biomarkers and skin barrier function). The overarching purpose of this longitudinal study is to understand how the abundance of skin S. aureus (and several c... Read More
Gender:
ALL
Ages:
13 years and above
Trial Updated:
06/03/2024
Locations: University of Rochester Medical Center, Rochester, New York
Conditions: Atopic Dermatitis, Psoriasis
Register for Updates
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
NCT05635266
Recruiting
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and preventative methods for specific and complex conditions.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
05/03/2024
Locations: Sanguine Biosciences, Waltham, Massachusetts
Conditions: Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
Register for Updates